收费全文 | 193092篇 |
免费 | 33459篇 |
国内免费 | 2618篇 |
耳鼻咽喉 | 5516篇 |
儿科学 | 6554篇 |
妇产科学 | 3569篇 |
基础医学 | 8898篇 |
口腔科学 | 2406篇 |
临床医学 | 30842篇 |
内科学 | 56258篇 |
皮肤病学 | 8235篇 |
神经病学 | 19219篇 |
特种医学 | 7737篇 |
外科学 | 46316篇 |
综合类 | 405篇 |
现状与发展 | 72篇 |
一般理论 | 19篇 |
预防医学 | 10206篇 |
眼科学 | 4067篇 |
药学 | 3666篇 |
1篇 | |
中国医学 | 91篇 |
肿瘤学 | 15092篇 |
2024年 | 736篇 |
2023年 | 5187篇 |
2022年 | 2130篇 |
2021年 | 4756篇 |
2020年 | 6939篇 |
2019年 | 3560篇 |
2018年 | 8946篇 |
2017年 | 8398篇 |
2016年 | 9596篇 |
2015年 | 9815篇 |
2014年 | 17389篇 |
2013年 | 18028篇 |
2012年 | 9212篇 |
2011年 | 9198篇 |
2010年 | 12159篇 |
2009年 | 15883篇 |
2008年 | 8721篇 |
2007年 | 6868篇 |
2006年 | 9060篇 |
2005年 | 6309篇 |
2004年 | 5148篇 |
2003年 | 3896篇 |
2002年 | 3760篇 |
2001年 | 3990篇 |
2000年 | 3144篇 |
1999年 | 3415篇 |
1998年 | 3906篇 |
1997年 | 3662篇 |
1996年 | 3542篇 |
1995年 | 3368篇 |
1994年 | 2079篇 |
1993年 | 1675篇 |
1992年 | 1463篇 |
1991年 | 1485篇 |
1990年 | 1125篇 |
1989年 | 1225篇 |
1988年 | 1050篇 |
1987年 | 890篇 |
1986年 | 919篇 |
1985年 | 745篇 |
1984年 | 584篇 |
1983年 | 541篇 |
1982年 | 549篇 |
1981年 | 423篇 |
1980年 | 379篇 |
1979年 | 316篇 |
1978年 | 340篇 |
1977年 | 410篇 |
1975年 | 285篇 |
1972年 | 310篇 |
Objective
To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline. 相似文献Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
Methods: Patients were divided into two groups: Group A (22 patients) who underwent ACL reconstruction performed with an All-Inside graft-link technique; Group B (22 patients) who underwent ACL reconstruction with an Out-In technique and DGST graft. At a mean follow-up of 13 months, quadriceps and hamstring isokinetic peak torque deficits were recorded.
Results: In group A, the mean side to side peak torque flexion difference between the operated and non-operated limbs was ?3% and the mean torque at 30° was ?7.5% at high angular velocity (180°/sec); the mean peak flexion torque was 7.2% and the mean torque at 30° was 3.1% at low angular velocity (60°/sec).
In group B, the mean side to side peak flexion torque was ?3.5% and the mean torque at 30° was ?7.6% at high angular velocity (180°/sec); the mean peak flexion torque was ?7.2% and the mean torque at 30° was ?11% at low angular velocity (60°/sec).
A statistically significant difference was found between the two groups at lower angular velocity both for the mean peak flexion torque and the mean torque at 30° (p = 0.009), with better results in the study group.
Discussion/conclusion: Gracilis sparing technique is a minimally invasive technique for ACL reconstruction and yielded a significantly better flexion strength recovery at lower angular velocity compared to a full tibial tunnel technique with DGST for ACL reconstruction. 相似文献